Overview

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

Status:
Active, not recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

This study is being done to determine if treatment with azacitidine and venetoclax is effective treatment for elderly patients with acute myeloid leukemia (AML) who have not received previous treatment. Azacitidine and venetoclax will be given as induction treatment followed by venetoclax maintenance treatment for patients who respond to the induction treatment.

Phase:

Phase 2

Details

Lead Sponsor:

University of Colorado, Denver

Treatments:

Azacitidine
Venetoclax